Quanterix

QTRX · NASDAQ

$2.72−$0.05 (−1.81%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.77

Latest news

NewsOct 7, 8:02 AM ET
Quanterix, Innovita Biological Technology Receives Regulatory Nods From China For Quanterix SIMOA Technology, Neurology Biomarker Testing
Press releaseOct 7, 8:00 AM ETBusiness Wire
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
Press releaseSep 25, 8:00 AM ETBusiness Wire
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Press releaseSep 16, 9:00 PM ETBusiness Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 14, 8:00 AM ETBusiness Wire
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
NewsAug 24, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsAug 14, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsAug 10, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 10, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseAug 10, 8:01 AM ETBusiness Wire
Quanterix Names Jim Gute Chief Commercial Officer
Press releaseAug 10, 8:00 AM ETBusiness Wire
Quanterix Releases Financial Results for the Second Quarter of 2026
Press releaseAug 6, 8:00 AM ETBusiness Wire
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Press releaseAug 4, 8:00 AM ETBusiness Wire
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
Press releaseJul 16, 4:05 PM ETBusiness Wire
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 14, 4:29 PM ETBusiness Wire
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
NewsJun 24, 4:39 AM ETMohd Haider
Quanterix Stock Is Popping In Pre-Market: Here's Why
Press releaseJun 16, 4:01 PM ETBusiness Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 9, 8:03 AM ETBusiness Wire
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Press releaseJun 4, 8:02 AM ETBusiness Wire
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Press releaseJun 3, 8:01 AM ETBusiness Wire
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 26, 4:01 PM ETBusiness Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 12, 4:01 PM ETBusiness Wire
Quanterix Announces Planned Transition of Chief Financial Officer
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:01 PM ETBusiness Wire
Quanterix Releases Financial Results for the First Quarter of 2026
Press releaseMay 6, 8:00 AM ETBusiness Wire
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
Press releaseApr 24, 8:33 AM ETBusiness Wire
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Press releaseApr 24, 8:33 AM ETBusiness Wire
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Press releaseApr 17, 8:33 AM ETBusiness Wire
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
Press releaseApr 15, 8:33 AM ETBusiness Wire
Quanterix Debuts Content Innovation Engine at AACR 2026
Press releaseMar 27, 4:00 PM ETBusiness Wire
Quanterix Corporation Announces Date of 2026 Annual Meeting
NewsMar 2, 4:23 PM ET
Quanterix Earnings Report: Q4 Overview
Press releaseMar 2, 4:01 PM ETBusiness Wire
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Press releaseMar 2, 8:33 AM ETBusiness Wire
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
NewsMar 2, 6:11 AM ET
Earnings Scheduled For March 2, 2026
NewsFeb 27, 1:01 PM ET
Earnings Outlook For Quanterix
NewsJan 9, 12:21 PM ETAvi Kapoor
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
NewsNov 10, 6:12 AM ET
Earnings Scheduled For November 10, 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Quanterix, Innovita Biological Technology Receives Regulatory Nods From China For Quanterix SIMOA Technology, Neurology Biomarker Testing

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Quanterix Names Jim Gute Chief Commercial Officer

Quanterix Releases Financial Results for the Second Quarter of 2026

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Quanterix Stock Is Popping In Pre-Market: Here's Why

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Announces Planned Transition of Chief Financial Officer

Earnings Scheduled For May 6, 2026

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Quanterix Corporation Announces Date of 2026 Annual Meeting

Quanterix Earnings Report: Q4 Overview

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

Earnings Scheduled For March 2, 2026

Earnings Outlook For Quanterix

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Earnings Scheduled For November 10, 2025